Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, while the USPTO allowed a patent for biomarker-guided use of LP-184 in multiple cancers. LP-284 showed a complete metabolic response in a Phase 1 DLBCL patient, and LP-184 demonstrated a 45% disease control rate in advanced solid tumors.
NEOK Bio dosed first patients in Phase 1 trials of lead bispecific ADCs NEOK001 and NEOK002 for advanced solid tumors. The candidates target B7-H3/ROR1 and EGFR/MUC1, with initial data expected in 2027.
The FDA has cleared CStone Pharmaceuticals' investigational new drug application to begin a Phase II trial of its trispecific antibody CS2009 in advanced solid tumors. The multicenter trial will evaluate monotherapy and combination regimens across nine cancer types in Australia, China, and the U.S. Initial Phase I data showed a favorable safety profile and encouraging antitumor activity.
BioNTech presented phase 2 data for HER2-directed ADC Trastuzumab Pamirtecan showing 47.9% response rate in endometrial cancer, with FDA submission planned for 2026. BioLineRx dosed first patient in phase 1/2a GLIX1 trial for glioblastoma and reported new preclinical data. Both companies presented at ASCO 2026.
A phase 1 study found MP0317, a FAP-targeting CD40 agonist, showed tumor-localized CD40 activation, a favorable safety profile, and immune remodeling in advanced solid tumors.
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
Crescent Biopharma dosed the first patient in its ASCEND Phase 1/2 trial of CR-001, a PD-1 x VEGF bispecific antibody for solid tumors. The company also reported Q1 2026 results and outlined pipeline milestones including ADC combination trials expected in the second half of 2026.
The FDA granted fast track designation to SIM0505, a CDH6-targeting antibody-drug conjugate, for platinum-resistant ovarian cancer based on preclinical and early clinical data. A phase 1 trial is currently evaluating the drug in advanced solid tumors, with initial data expected at the 2026 ASCO conference. The company plans to begin dose optimization studies in ovarian cancer patients in Q2 2026.
Dewpoint Therapeutics has initiated a Phase 1a/2a clinical trial for DPTX3186, a first-in-class therapy targeting biomolecular condensates in advanced solid tumors. The drug's development is based on foundational research from Whitehead Institute on cellular organization and gene regulation. The trial represents an early clinical evaluation of condensate-based therapeutics for cancer treatment.
Adagene and Incyte will collaborate on a Phase 1 study combining muzastotug with INCA33890 for MSS colorectal cancer patients, beginning in 2026. The collaboration marks the second instance where Adagene's SAFEbody technology is paired with a PD-1-based bispecific. Muzastotug has shown encouraging response rates in combination with pembrolizumab in previous trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779798 |
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma. |
NOT_YET_RECRUITING | PHASE1 |
| NCT07775703 |
HS-20117-2 Injection in Patients With Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT07774611 |
An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07772934 |
VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07767474 |
A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07753590 |
A Clinical Study to Evaluate Single-agent Therapy of BR113 for Injection in Patients With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07750132 |
Phase I Study of SM2275 Injection in Patients With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07744763 |
A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT07743723 |
A Study of IOV-5001 in Adults With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07738679 |
Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE2 |
